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Abstract
Secreted protein acidic and rich in cysteine (SPARC) is also known as BM-40 or Osteonectin, a multi-functional protein
modulating cell–cell and cell–matrix interactions. In cancer, SPARC is not only linked with a highly aggressive phenotype,
but it also acts as a tumor suppressor. In the present study, we sought to characterize the function of SPARC and its role in
sensitizing neuroblastoma cells to radio-therapy. SPARC overexpression in neuroblastoma cells inhibited cell proliferation in
vitro. Additionally, SPARC overexpression significantly suppressed the activity of AKT and this suppression was accompanied
by an increase in the tumor suppressor protein PTEN both in vitro and in vivo. Restoration of neuroblastoma cell radio-
sensitivity was achieved by overexpression of SPARC in neuroblastoma cells in vitro and in vivo. To confirm the role of the
AKT in proliferation inhibited by SPARC overexpression, we transfected neuroblastoma cells with a plasmid vector carrying
myr-AKT. Myr-AKT overexpression reversed SPARC-mediated PTEN and increased proliferation of neuroblastoma cells in
vitro. PTEN overexpression in parallel with SPARC siRNA resulted in decreased AKT phosphorylation and proliferation in vitro.
Taken together, these results establish SPARC as an effector of AKT-PTEN-mediated inhibition of proliferation in
neuroblastoma in vitro and in vivo.
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Introduction
Neuroblastoma is the most common extracranial solid tumor in
children under the age of five years. When neuroblastoma is first
diagnosed, 50 percent of the patients are considered to be high-risk
patients. Neuroblastoma originates from neural crest cells and
these tumors, which are normally dissimilar both clinically and
biologically, are found in the adrenal medulla or near the
sympathetic chain [1]. Neuroblastoma in infants may regress
spontaneously while tumors in older patients may settle into
benign ganglioneuromas. Neuroblastoma is caused by rapid cell
production by the neuroblast during fetal growth, which causes a
growth or a tumor to develop. Usually, these tumors cannot be
removed completely through surgery due to metastasis at the time
of diagnosis and have a very poor prognosis. Metastasis is a
complex process mainly dependent on cell adhesion to the
extracellular matrix (ECM) and basement membrane and takes
place through a multi-step process that includes cell infiltration
from the primary tumor, intravascular invasion, and eventually
proliferation to the metastatic site [2,3] Although intensive
multimodality therapies have produced some developments in
the overall cure rate of these tumors, the therapies have
considerable short- and long-term toxicities. Thus, a detailed
knowledge of mechanisms controlling proliferation and differen-
tiation may lead to a better understanding of the molecular
pathogenesis of neuroblastoma, which may result in novel
biologically-based therapies that are less toxic and more effective.
While the ECM is classically thought to instruct cell behavior
primarily through biochemical recognition by cell adhesion
receptors, signals encoded in the ECM may play a significant
role in guiding neuroblastoma differentiation and proliferation.
Overall, the mechanical stringency of the ECM can intensely alter
cellular behavior, including morphology, motility, and prolifera-
tion [4–6]. The matricellular proteins are extracellular proteins
and do not contribute structurally to the extracellular environment
as do the classical extracellular matrix proteins, but instead they
modulate interactions between the extracellular matrix and cells.
One such matricellular protein is Secreted Protein Acidic and
Rich in Cysteine (SPARC), also known as osteonectin or BM-40, a
34 kDa, calcium-binding glycoprotein shown to associate with the
cell membrane and membrane receptors [7,8]. SPARC is known
to not only modulate cell–cell and cell–matrix interactions, but
also to influence de-adhesive and growth regulatory properties [9].
In cancers, SPARC may elicit different actions, showing the
complexity of the protein [10,11]. In certain types of cancers, like
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aggressive tumor phenotype [9], whereas in other cancers, mainly
ovarian, neuroblastomas, colorectal and PNET tumors, SPARC
may function as a tumor suppressor [9,12]. Recent studies show
that SPARC modulates cellular functions and proliferation
through modulation of different growth factor signaling [13]. In
addition, we have shown that SPARC inhibits medulloblastoma
tumor growth both in vitro and in vivo by inducing autophagy-
mediated cell death and causing neuronal differentiation [14].
The tumor suppressor phosphatase and tensin homolog deleted
on chromosome 10 (PTEN) is a phosphatase, which is deleted or
mutated in a variety of human cancers [15–17]. PTEN plays an
important role in keeping the processes of cell migration and
proliferation under control. PTEN is a negative regulator of
phosphatidylinositol-3-kinase (PI3K) signaling by dephosphorylat-
ing phosphatidylinositol- 3–5-triphosphate (PIP3). However, very
little is known about the existence of other substrates for PTEN,
with the exception of PtdIns-3,4,5-P3 and PtdIns-3,4-P2, which
are required for the phosphorylation and activation of the AKT
protein kinase, a survival factor that fuels the progression of the
cell cycle [18–20] and also prevents cells from undergoing
apoptosis by inhibiting pro-apoptotic factors as well as nuclear
translocation of the forkhead transcription factors [21–23].
Earlier studies from our laboratory and others have shown that
high levels of SPARC correlate with inhibited proliferation in
many cancer types. We have shown that SPARC overexpression
by an adenoviral vector induced autophagy-mediated apoptosis in
PNET tumor cells. In the present study, we sought to further
characterize the mechanism by which SPARC is capable of
inhibiting proliferation in neuroblastoma cells.
Results
Overexpression of SPARC in neuroblastoma cells in vitro
SPARC, a prototype of the matricellular protein family, has
been shown to play an important role in various aspects of
tumorigenesis including tumor invasion, angiogenesis and tumor
growth [12]. To elucidate the effect of SPARC overexpression
using a genetic approach and to observe its effects on neuroblas-
toma tumor growth in vitro and in vivo, we subcloned a human
SPARC cDNA in a pcDNA3.1 mammalian expression vector and
transfected it into SK-N-AS, NB-1691 and IMR-32 neuroblasto-
ma cells. Figure S1A shows that SPARC protein levels were
increased in the three cell lines when compared to mock or empty
vector-transfected cells. We observed a ,3- to 4-fold increase in
SPARC protein levels in pSPARC-transfected cells compared to
controls. To confirm that this upregulation of SPARC mRNA
translated into increased levels of SPARC protein, we assessed
mRNA transcript levels in the pSPARC-transfected cells. SPARC-
overexpressed neuroblastoma cells showed a 3- to 4-fold increase
in mRNA levels when compared to mock or empty vector-
transfected cells (Fig. S1B). As assessed by immunofluorescence
microscopy, intense staining for SPARC was observed in all three
cell lines transfected with pSPARC when compared to mock or
empty vector-transfected cells (Fig. S1C). We compared the
SPARC levels in tumor cells with HMEC cells (as control cells)
and did not find much change in SPARC levels (Fig. S1D).
X-ray radiation inhibits SPARC expression in
neuroblastoma cells
SPARC has been shown to be a therapy-resistant reversal gene
whose expression was significantly decreased in resistant cancer
cells [24]. To determine whether there was a dose-dependent
radiation effect on these cells we performed an in vitro clonogenic
assay to characterize the survival of neuroblastoma cells, after
exposure to ionizing radiation. SK-N-AS, NB1691 and IMR-32
cells were given a single dose of radiation (from 2 Gy to 12 Gy)
and assayed for survival. Irradiated cells showed a dose-dependent
decrease in survival fraction with a 27.6% survival rate at 8 Gy for
SK-N-AS, a 30% survival rate at 8 Gy for NB1691 and a 25%
survival rate at 4 Gy for IMR-32 cells when compared to non-
radiated cells (Fig. S1E). To examine the effect of radiation on
SPARC expression, we determined SPARC protein levels in SK-
N-AS, NB1691 and IMR-32 neuroblastoma cells. Figure 1A
indicates that SPARC expression levels were inhibited with
radiation in a dose-dependent manner when compared to non-
irradiated cells. Densitometric analysis revealed about 30–40%
inhibition in SPARC levels when cells were treated with 8 Gy (SK-
N-AS and NB1691) and 4 Gy in IMR-32 cells as compared to
non-irradiated cells.
SPARC overexpression inhibits proliferation in
neuroblastoma cells
We next examined the possible role of SPARC in radiation
response. Inhibition of SPARC levels by radiation was restored
using a plasmid vector encoding the SPARC full-length gene.
SPARC overexpression in neuroblastoma cell lines prior to
irradiation exhibited increased SPARC protein and transcript
levels in neuroblastoma cell lines (Fig. 1B) when compared to
mock or empty vector-treated cells prior to irradiation. Densito-
metric analysis for SPARC protein and transcript levels showed a
3- to 4-fold increase (Fig. 1B) in the pSPARC treatment prior to
irradiation. Further, we assessed the sensitivity of neuroblastoma
cells to SPARC overexpression in combination with radiation
using the MTT proliferation assay. The results revealed that
SPARC-overexpressed cells had increased sensitivity to radiation,
and their proliferation rate was less than that of cells treated with
radiation alone or combined with mock or empty vector treatment
(Fig. 1C). We also assessed the impact of the combination
treatment on neuroblastoma cells using clonogenic survival assay
and found that combining SPARC and ionizing radiation resulted
in increased cell death (Fig. 1D). To further confirm the effect of
SPARC overexpression on neuroblastoma cell growth, we
performed TUNEL assay. SPARC overexpression in neuroblas-
toma cell lines prior to irradiation exhibited increased TUNEL
positive cells compared to that of cells treated with radiation alone
or combined with mock or empty vector treatment (Fig1E). To
further confirm this result, we also analyzed cleavage of PARP and
caspase3 by western blot analysis. Western blot analysis revealed
that SPARC overexpression in neuroblastoma cell line (SK-N-AS)
prior to irradiation exhibited increased cleavage of capspase3 and
PARP when compared to that of cells treated with radiation alone
or combined with mock or empty vector treatment (Fig. 1F).
SPARC overexpression abates irradiation-induced cell
cycle arrest in neuroblastoma cells
When cells are exposed to radiation, they initiate a complex
response that includes the arrest of cell cycle progression [25].
DNA is an important subcellular target of ionizing radiation, but
oxidative damage to plasma membrane lipids initiates signal
transduction pathways that activate apoptosis and may play a role
in cell cycle regulation [26]. Moreover, irradiation-induced G2
arrest was shown to require inhibitory phosphorylation of the
kinase Cdc2 [27]. To identify whether the growth inhibitory effect
in cells that received the combined treatment of radiation and
SPARC overexpression was caused by specific perturbation of cell
cycle-related events, DNA contents of neuroblastoma cells were
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using neuroblastoma cells treated with mock, empty vector (pEV),
pSPARC with and without radiation (IR) demonstrated a
significant increase in the proportion of G2/M cells and a reduced
number of G1 cells after IR treatment when compared to controls.
However, SPARC treatment prior to IR increased the number of
Figure 1. Irradiation inhibits SPARC expression and inhibits proliferation of neuroblastoma cells. (A) SK-N-AS, NB1691 and IMR-32 cells
were irradiated (IR) with X-ray (0–12 Gy), incubated for 12 hours, and cells were collected. (A) SPARC expression was determined by western blot
analysis in cell lysates. Results are representative of three independent experiments. GAPDH served as a loading control. Columns, mean of three
experiments; bars, SD. (B) Neuroblastoma cell lines SK-N-AS, NB1691 and IMR-32 cells were transfected with mock (PBS control), empty vector (pEV)
or pSPARC for 24 hours, and SK-N-AS and NB1691cells were irradiated with 8 Gy and IMR-32 cells were irradiated with 4 Gy dose of radiation. Left
panel: SPARC levels were determined by Western blot analysis using a SPARC-specific antibody. GAPDH served as a loading control. Middle panel:
cDNA was produced from total RNA extracted from the mock and infected cells. RT-PCR was performed for SPARC. Results are representative of three
independent experiments. GAPDH served as a control for RNA quality. Right panel: Densitometric analysis showing levels of SPARC protein and
mRNA levels. Columns, mean of three experiments; bars, SD. * p,0.01 vs pEV; ** p,0.01 vs IR+pEV. (C) SK-N-AS, NB-1691 and IMR-32 cells were
transfected with mock, pEV or pSPARC and at the indicated time points, the plates were incubated by adding MTT reagent for a further 6 hours. The
developed purple color Formazan crystals were solubilized using DMSO, and color intensity was measured using a spectrophotometer at 570 nm.
Data were plotted as absorbance at 570 nm. Results are representative of three independent experiments. Points, mean of three experiments.
H=hours. (D) SK-N-AS, NB1691 and IMR-32 neuroblastoma cells were transfected with mock, pEV or pSPARC. After 24 hours of incubation, SK-N-AS
and NB1691 cells were irradiated with 8 Gy; IMR-32 cells were irradiated with 4 Gy and clonogenic assay was performed as described in Materials and
Methods. The cells were cultured and colonies larger than 50 cells were counted. Columns: mean of triplicate experiments; bars: SD. (E) SK-N-AS,
NB1691 and IMR-32 neuroblastoma cells were transfected with mock, pEV or pSPARC. After 24 hours of incubation, SK-N-AS and NB1691 cells were
irradiated with 8 Gy and cultured for another 16 hours. TUNEL assay was performed as per the manufacturer’s procedure. (F) SK-N-AS neuroblastoma
cells were transfected with mock, pEV or pSPARC. After 24 hours of incubation, cells were irradiated with 8 Gy and cultured for another 16 hours.
Western blot analysis was performed for Caspase3 and PARP specific antibodies and GAPDH served as loading control.
doi:10.1371/journal.pone.0036093.g001
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shown in Figure 2A, treatment of neuroblastoma cells with
radiation resulted in an increase in the percentage of G2/M cells
(from 10% to ,50%) as compared to control, non-irradiated cells.
In cells transfected with pSPARC prior to radiation, the
percentage of cells in the sub-G1 phase increased to a maximum
of 20%.
Functional defect in DNA damage checkpoint pathways showed
increased sensitivity to radiation and other DNA damage agents
[28,29]. This observation suggests a possibility that components of
these DNA damage checkpoint pathways may serve as potential
therapeutic targets for enhancing radiosensitivity of tumor cells
[30]. To test this hypothesis, we evaluated the protein levels of
Chk1 and phospho-Cdc25C in SPARC-overexpressed neuroblas-
toma cells. Irradiated neuroblastoma cell lines exhibited a
significant increase in Chk1 levels but not in Chk2 levels. Further,
irradiation-induced Chk1 levels were increased in cells treated
with pSPARC prior to IR (Fig. 2B). Densitometric analysis for
Chk1 and Cdc25C indicated 3- to 4-fold increase in SPARC-
overexpressed cells when compared to mock or empty vector-
treated cells (Fig. 2B). Recent studies showed that Chk1, a serine-
threonine kinase, is critical for G2/M arrest in response to DNA
damage and is also known to modulate Cdc25C. We next
determined the levels of Cdc25C by western blotting and found
that irradiation increased the levels of Cdc25C protein levels when
compared to non-irradiated cells. This increase was further
enhanced by SPARC overexpression, thereby suggesting that
SPARC overexpression in neuroblastoma cells abates cell cycle
arrest and leads to decreased proliferation. Cyclin B is known to be
one of the regulatory proteins involved in mitosis and forms a
complex with Cdc2. Here, we sought to determine the levels of
these proteins by western blotting. Our results demonstrated that
Cyclin B and Cdc2 levels were increased in the combination
treatment (Fig. 2B), indicating that irradiation-induced G2/M cell
cycle arrest was abating by SPARC overexpression in neuroblas-
toma cells.
SPARC overexpression decreases radiation-induced PI3K-
AKT and PTEN signaling
Ionizing or ultraviolet radiation-induced cellular survival
signaling pathways induce development of cancer and insensitivity
of tumor cells to radiation therapy [31]. Collecting evidence
suggests that the phosphatidylinositide 3-kinase (PI3K)/AKT
signal pathway is an important contributor to radioresistance
[31]. In many cell types, PI3K/AKT signaling is a key
cytoprotective response downstream of the EGFR family receptors
and mediates carcinogenesis [31]. The phosphatase and tensin
homologue (PTEN) is also a negative regulator of proliferation in
many cancer types. Furthermore, AKT activity is elevated in cell
lines with the mutated PTEN tumor suppressor gene. Therefore,
we sought to characterize the effects of physiologic and genetic
manipulation of AKT signaling on combined treatments of IR and
Figure 2. SPARC overexpression sensitizes neuroblastoma cells to radiation by abating irradiation-induced cell cycle arrest. SK-N-
AS, NB1691 and IMR-32 cells were transfected with mock (PBS control), empty vector (pEV) or with pSPARC for 24 hours, and SK-N-AS and
NB1691cells were irradiated (IR) with 8 Gy and IMR-32 cells were irradiated with 4 Gy dose of radiation. (A) Cells were collected and subjected to
FACS analysis with propidium iodide staining for DNA content and represented in a graphical manner. Results are representative of three
independent experiments. Columns: mean of triplicate experiments. (B) Cells were collected and the cell lysates were subjected to western blotting
for Chk1, Chk2, Cdc25C, Cyclin B1, Cdc2 and pCdc2. Results are representative of three independent experiments. Densitometric analysis for Chk1 and
Cdc25C is shown in the corresponding bar graph. Columns, mean of triplicate experiments; bars, SD. * p,0.01 vs pEV; ** p,0.01 vs IR+pEV.
doi:10.1371/journal.pone.0036093.g002
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first assessed the expression levels of EGFR and PI3K/AKT
signaling molecules in the combination treatment. Radiation-
induced EGFR phosphorylation and PI3K/AKT levels were
inhibited and PTEN levels were increased by SPARC overex-
pression prior to irradiation in neuroblastoma cells (Fig. 3A).
SPARC overexpression prior to irradiation decreased pAKT levels
by 60–70% when compared to mock or empty vector-treated
controls (Fig. 3B); PTEN levels were increased up to 3- to 4-fold in
SPARC-overexpressed neuroblastoma cells when compared to
mock or empty vector-treated cells (Fig. 3B) as determined by
densitometry analysis.
PTEN is capable of modulating the c-Myc gene and has been
implicated in the control of cell proliferation, differentiation, and
pathogenesis of malignant diseases. We next determined the levels
of c-Myc in the combination treatment and observed that c-Myc
levels were inhibited by SPARC overexpression, thereby indicat-
ing a role of PI3K/AKT signaling in neuroblastoma cell
proliferation. AKT has been shown to play an important role in
several cellular functions such as cell survival, growth, prolifera-
tion, migration, metabolism and angiogenesis [32]. It is clear that
AKT has the capacity to act on the substrates affecting various
cellular signaling pathways and it was of interest to us to check the
role of AKT overexpression in the SPARC-mediated effect of
neuroblastoma cell proliferation. To confirm the role of PI3K/
AKT pathway in SPARC-overexpressed neuroblastoma cell
proliferation, studies were performed using myristoylated (consti-
tutively active) AKT (myr-AKT) overexpression. Earlier reports
showed that decreased Chk1 can inhibit the G2 cell cycle arrest
[33]. Therefore, we first determined the levels of Chk1 in AKT
overexpressed pSPARC-transfected neuroblastoma cells. Activa-
tion of AKT signaling by myr-AKT in the SPARC-overexpressed
neuroblastoma cells led to decreased cell cycle check point Chk1
(Fig. 4A). In parallel, activation of AKT inhibits SPARC-induced
PTEN in neuroblastoma cells (Fig. 4A). To confirm the role of
collective inhibition of Chk1 and PTEN on proliferation, we
assessed the proliferation rate using MTT assay in AKT
overexpressed, pSPARC-transfected cells with or without radia-
tion. The results clearly demonstrate that overexpression of
constitutively active AKT led to increased proliferation in
irradiated and non-irradiated cells with pSPARC transfection
(Fig. 4B).
SPARC overexpression induces c-Jun activation and leads
to increased PTEN
In certain cancers SPARC is known to increase the levels and
activity of the transcription factor c-Jun [34]. We sought to
determine the levels of JNK activation as this can potentiate
transcriptional activity of c-Jun by phosphorylating serines 63 and
73 [35]. Western blot analysis revealed that SPARC overexpres-
sion increased the phosphorylation of JNK by about 2–3 fold in all
the cell lines when compared with mock or empty vector-treated
neuroblastoma cells (Fig. 5). We evaluated the levels of phosphor-
ylation of c-Jun at serine 63 and 73 upon SPARC overexpression.
SPARC overexpression led to increased p-c-Jun (Ser-63) and p-c-
Jun (Ser-73) when compared to mock and empty vector-
transfected cells (Fig. 5). As JNK is a known modulator of PTEN
[36], we further tested whether inhibition of JNK activation will
suppress PTEN in neuroblastoma cells. We found that inhibition
of JNK using the JNK activation inhibitor reduced the level of
PTEN in SPARC overexpressed cells when compared with non-
treated SPARC overexpressed neuroblastoma cells (Fig. 5).
PTEN overexpression inhibits proliferation in SPARC-
inhibited neuroblastoma cells
Direct inhibition of signaling pathways that are negatively
regulated by PTEN suppress proliferation and migration in
SPARC-expressing GBM cells in vitro [37]. PTEN is a negative
regulator of AKT that is often mutated or deleted in AIPC,
resulting in AKT-mediated survival signaling, which confers
chemotherapeutic resistance in AIPC [38]. To examine the effect
of PTEN on the phosphorylation status of AKT cell survival
Figure 3. SPARC overexpression inhibits AKT phosphorylation and induces PTEN. SK-N-AS, NB1691 and IMR-32 cells were transfected with
mock (PBS control), empty vector (pEV) or with pSPARC for 24 hours, and SK-N-AS and NB1691cells were irradiated (IR) with 8 Gy and IMR-32 cells
were irradiated with 4 Gy dose of radiation for further 16 hours. (A) Cell lysates were assessed for EGFR, AKT and their phosphorylations, PI3K, mTOR,
PTEN and c-Myc by western blotting. (B) Protein levels were quantified by densitometric analysis for pAKT and PTEN is shown in the corresponding
bar graph. Columns, mean of triplicate experiments; bars, SD. Results are representative of three independent experiments. * p,0.01 vs pEV; **
p,0.01 vs IR+pEV.
doi:10.1371/journal.pone.0036093.g003
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neuroblastoma cells. The neuroblastoma cells (SK-N-AS, NB-
1691 and IMR-32) were transfected with either SPARC siRNA or
with non-specific siRNA for 24 hours, and then treated with
PTEN-overexpressing plasmid for a further 24 hours. The results
suggested a significant reduction of phosphorylated AKT in
SPARC-inhibited neuroblastoma cell lines when PTEN was
overexpressed, suggesting that PTEN plays an important role in
inhibition of proliferation with the combination treatment
(Fig. 6A). MTT assay of the PTEN-overexpressed neuroblastoma
cells showed decreased proliferation at the 72-hour time point in
SPARC-inhibited cells to 70%, 62% and 75% in SK-N-AS,
NB1691 and IMR-32 cells, respectively (Fig. 6B)
SPARC overexpression inhibits in vivo growth capacity of
neuroblastoma cells in SCID mice
To assess the effect of SPARC overexpression on sensitizing
tumors to radiotherapy, NB1691 neuroblastoma cells were
orthotopically injected into the right adrenal gland of SCID mice.
After one week of treatments, tumors were removed and fixed in
10% phosphate-buffered formaldehyde. Significant reduction in
tumor growth was observed in mice treated with SPARC alone or
with SPARC in combination with radiation as compare to mice
treated with controls with or without radiation (Fig. 7A). H&E
staining for tumor sections showed decreased tumor volume in
SPARC-overexpressed mice when compared to mock or empty
vector-treated mice with or without radiation (Fig. 7B). To
determine SPARC overexpression in vivo, tumor sections were
stained with a monoclonal antibody for human SPARC. Figure 7C
indicates that tumor sections from pSPARC alone or in
combination with radiation treatment showed intense staining
for SPARC as compared to radiation alone or in combination with
mock or the pEV treatment. To assess whether reduced tumor
growth was due to inhibition of tumor cell proliferation, we
analyzed the levels of Ki67 in the tumor sections. Ki67 staining
was found to be higher in mock or pEV treatment alone or in
Figure 4. Constitutively active AKT overexpression blocks the radiosensitization capability of SPARC in neuroblastoma cells. SK-N-
AS, NB1691 and IMR-32 cells were transfected with mock (PBS control), empty vector (pEV) or with pSPARC alone or in combination with plasmid
overexpressing constitutively active AKT (myrAKT; pAKT) for 24 hours, and SK-N-AS and NB1691cells were irradiated with 8 Gy and IMR-32 cells were
irradiated with 4 Gy dose of radiation and incubated for further 16 hours. (A) Cell lysates were assessed for SPARC, pAKT, EGFR, pEGFR, PTEN, c-Myc
and Chk1 by western blotting. Protein levels were quantified by densitometric analysis and shown in the corresponding bar graph. Columns, mean of
triplicate experiments; bars, SE. Results are representative of three independent experiments. (B) At the indicated time points, the plates were
incubated by adding MTT reagent for a further 6 hours. The developed purple color formazan crystals were solubilized using DMSO, and color
intensity was measured by spectrophotometer at 570 nm. Data are plotted at an absorbance of 570 nm. Results are representative of three
independent experiments. Points, mean of triplicate experiments. H=hours.
doi:10.1371/journal.pone.0036093.g004
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alone or in combination with radiation, thereby indicating that
SPARC overexpression in in vivo reduced tumor cell proliferation
(Fig. 7C). To determine whether inhibited proliferation in
SPARC-overexpressed tumors was due to decreased AKT and
increased PTEN levels, we analyzed AKT and PTEN levels in
these tumor sections using specific antibodies against pAKT and
PTEN. Tumor sections from either SPARC alone or in
combination with radiation showed moderate staining for pAKT.
In contrast, we found intense staining for PTEN when compared
to mock or pEV treatment alone or in combination with radiation
(Fig. 7C). These results are consistent with a role for AKT-PTEN
in SPARC-mediated inhibition of proliferation as observed in vitro.
Discussion
Earlier reports suggested that SPARC negatively regulates cell
proliferation in several cancers without stimulating metastasis [39].
In certain cancers, such as melanomas and gliomas, SPARC is
associated with a highly aggressive tumor phenotype. In other
cancers, mainly ovarian, neuroblastoma, and colorectal, SPARC
may function as a tumor suppressor [9]. These opposing effects on
cell growth, cell migration and tumor formation suggest that the
functions of SPARC are cell-specific and may be dependent upon
concentration as well as regulation of ECM components.
Earlier studies [40] were done to investigate the effects of
downregulated SPARC expression on the radiosensitivity of
human glioma U-87MG cells and its possible mechanism. With
a small-interfering RNA (siRNA) expression plasmid vector
targeting SPARC, these authors obtained the stably transfected
cells in which the expression of SPARC was successfully
downregulated. The cells were then irradiated and analyzed by
several methods, including clonogenic assay, flow cytometry,
comet assay, and western blotting. Clonogenic assay showed that
downregulation of SPARC expression enhanced cell survival after
radiation. Flow cytometry analysis indicated that SPARC siRNA
decreased cell apoptosis responding to irradiation. Analysis of
signaling molecules with western blotting showed that the level of
AKT phosphorylation was increased in irradiated U-87MG/
SPARCsiRNA cells. Further, cell-cycle analysis by flow cytometry
showed enhanced G2 accumulation in U-87MG/SPARCsiRNA
cells after irradiation. The data suggest that inhibition of SPARC
expression may diminish the radiosensitivity of human glioma U-
87MG cells. One of the mechanisms for this effect may be
associated with the reduced cell apoptosis responding to radiation,
which may be contributed by the phosphoinositide 3-kinase/AKT
pathway activation. Moreover, the authors hypothesized that
enhanced G2 accumulation and increased DNA repair may also
account for the decreased radiosensitivity. SPARC is also known
for sensitizing therapy-resistant tumors for either chemotherapy or
radiation.
Neuroblastoma is the most common pediatric solid tumor. This
aggressive embryonal malignancy of neural crest origin has a peak
age of onset of 22 months, and accounts for ,11% of all pediatric
cancers and 15% of all pediatric cancer deaths. With current
treatment protocols, including chemotherapy, stem cell transplan-
tation, radiation, and surgery, ,80% of high-risk patients go into
remission, although the majority relapse and succumb to therapy-
resistant tumors.
The role of SPARC in cell survival and death is complex.
SPARC was originally identified as a stress response gene [41] and
subsequently described as a c-Jun-responsive target gene that can
be repressed or induced depending on cell type [42,43]. On the
other hand, there is evidence in some contexts that SPARC
induces apoptosis in ovarian cancer cells [44] and modulates
sensitivity to chemotherapy in colon cancer cells by enhancing
apoptosis [45]. Therefore, the focus of this investigation was to
determine the role of SPARC in neuroblastoma cell proliferation.
Our earlier findings revealed that proliferation, adhesion, migra-
tion, invasion, and MMP-9 activity in medulloblastoma (data
published earlier) [12], could be inhibited by SPARC. We have
also shown in an earlier study that SPARC induced autophagy-
mediated apoptosis in PNET tumor cells [12]. Here, we sought to
determine the mechanism by which SPARC could inhibit
neuroblastoma cell proliferation. Moreover, SPARC overexpres-
sion increased the levels of tumor suppressor protein PTEN and
inhibited pro-proliferating protein AKT. These results demon-
Figure 5. SPARC overexpression activates JNK and JNK in turn activates PTEN. SK-N-AS, NB1691 and IMR-32 cells were transfected for
24 hours with mock (PBS control), empty vector (pEV) or with pSPARC and treated with or without JNK activation inhibitor (JNK-I) for another
12 hours. Cell lysates were assessed for pJNK, JNK, c-Jun, p-c-Jun (ser-63), p-c-Jun (ser-73) and PTEN by western blotting. Protein levels were
quantified by densitometric analysis and shown in the corresponding bar graph. Columns, mean of triplicate experiments; bars, SE. Results are
representative of three independent experiments. * p,0.01 vs pEV; ** p,0.01 vs pEV+JNK-I.
doi:10.1371/journal.pone.0036093.g005
SPARC Expression Inhibits Neuroblastoma Growth
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36093strate that SPARC has the potential to inhibit neuroblastoma cell
proliferation, thereby leading to reduced tumor growth.
In the present study, we used a plasmid encoding the SPARC
full-length gene for SPARC overexpression in the neuroblastoma
cell lines to determine proliferation rate and tumor growth. The
cells transfected with pSPARC showed a 3- to 4-fold increase in
protein levels (as determined by western blotting and immunocy-
tochemical analysis) and in gene transcript levels (as determined by
RT-PCR analysis) when compared to mock or empty vector-
transfected cells. SPARC overexpression inhibited neuroblastoma
cell proliferation as determined by MTT assay.
Previously, SPARC was shown to be an anticipated resistance-
reversal gene as evidenced by low SPARC expression in refractory
human MIP101 colon cancer cells [24]. Restoration of cells
radiosensitivity and chemosensitivity was achieved by re-expres-
sion of SPARC in tumor xenografts of colon cancer. Additionally,
mice treated with SPARC showed increased sensitivity to
chemotherapy, which led to significant regression of xenografted
tumors. Earlier reports showed that modulation of SPARC
expression affected colorectal cancer sensitivity to radiation and
chemotherapy [24]. In the present study, SPARC expression levels
were reduced with radiation in a dose-dependent manner in
neuroblastoma cell lines. SK-N-AS and NB1691 cells showed
radiation resistance until 8 Gy radiation, whereas IMR-32 cells
showed resistance only until 4 Gy. It is well known that when cells
are exposed to radiation, they cause a complex response that
includes cell cycle arrest in G1 and G2 phases [26,46]. DNA is an
important subcellular target of ionizing radiation, but oxidative
damage to plasma membrane lipids initiates signal transduction
pathways that activate apoptosis, which may play a role in cell
cycle regulation [47]. In this study, we illustrate that SPARC alters
the cell cycle and sensitizes neuroblastoma cells to radiation by
altering Chk1 and Cdc25C. Earlier reports [48] show that cyclin B
increase can also occur in the absence of spindle inhibition if c-
Myc deregulation is combined with inactivation of the p53 tumor
suppressor. Under these conditions, cyclin B1 protein is induced
but retains its normal cell cycle regulation. The authors show that
c-Myc and the loss of p53 cooperate to induce cyclin B1 mRNA
and protein. The central role of cyclin B1 in the maintenance of
genomic integrity is underscored by the consequences of its
Figure 6. PTEN overexpression inhibits neuroblastoma cell proliferation in SPARC-inhibited cells. SK-N-AS, NB1691 and IMR-32 cells
were transfected with mock (PBS control), empty vector (pEV) or with siRNA against SPARC (pSP-siRNA) alone or in combination with plasmid
overexpressing PTEN (pPTEN) for 24 hours. SK-N-AS and NB1691cells were irradiated (IR) with 8 Gy and IMR-32 cells were irradiated with 4 Gy dose of
radiation. (A) Cell lysates were assessed for SPARC, pAKT, PTEN, c-Myc and Chk1 by western blotting. (B) SK-N-AS, NB-1691 and IMR-32 cells were
transfected and irradiated as above, and at the indicated time points, the plates were incubated by adding MTT reagent for a further 6 hours. The
developed purple color formazan crystals were solubilized using DMSO, and color intensity was measured using a spectrophotometer. Data are
plotted as absorbance at 570 nm. Results are representative of three independent experiments. Points, mean of triplicate experiments. H=hours.
doi:10.1371/journal.pone.0036093.g006
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increase in the cyclin B levels in the SPARC treatment
MAPK families are known to play an important role in key
cellular processes including proliferation, differentiation, develop-
ment, transformation, and apoptosis [49]. We evaluated the levels
of JNK in SPARC-overexpressed neuroblastoma cells and found
increased activation of JNK. Earlier reports showed that the
treatment of the colon cancer cell line HT29 with the differen-
tiating agent sodium butyrate (NaBT) increased PTEN protein
and mRNA expression and also induced c-Jun NH2-terminal
kinase (JNK) activation. Inhibition of JNK by chemical or genetic
methods attenuated NaBT-induced PTEN expression [36]. We
observed that SPARC overexpression increased the activation of
JNK and led to increased PTEN levels which were inhibited by the
JNK specific inhibitor. Based on the these results, we hypothesize
that SPARC activates JNK and activated JNK leads to increased
PTEN levels in SPARC-overexpressed neuroblastoma cells.
SPARC overexpression in neuroblastoma cells prior to radia-
tion inhibited AKT phosphorylation and increased levels of the
PTEN tumor suppressor protein. Accumulating evidence suggests
that the phosphatidylinositide 3-kinase (PI3K)/AKT signal path-
way is a major contributor to radioresistance [31]. Earlier reports
suggested that activation of the PI3K/AKT pathway is also
associated with tumorigenesis and resistance to apoptosis [50,51].
To confirm the role of the AKT pathway in sensitizing SPARC
capabilities towards radiation in neuroblastoma, we overexpressed
activated AKT using myr-AKT. The results suggest that activation
of AKT in the presence of SPARC overexpression led to increased
proliferation in neuroblastoma cells prior to radiation. We further
determined that phosphorylation of EGFR was inhibited with
SPARC overexpression prior to radiation in these cells. In many
cell types, PI3K/AKT signaling is a key response downstream of
the EGFR family of receptors and mediates carcinogenesis [31].
Moreover, AKT activity is commonly dysregulated in a variety
of human tumors because of frequent inactivation of the PTEN
tumor suppressor gene, which negatively regulates phosphatidy-
linositol 3 phosphate levels [52,53]. Moreover, alterations of this
gene have been identified in a large fraction of cancers [36,54,55].
In light of this, we postulate that increased PTEN function with
subsequent inhibition of SPARC prior to radiation reduced AKT
phosphorylation, thereby leading to decreased proliferation in
neuroblastoma cells. PTEN reduced AKT signaling in both
control and SPARC-overexpressing cells, suggesting that PTEN
signaling works as a downstream effector for SPARC overexpres-
sion in neuroblastoma cells. In the current study, we found that
SPARC overexpression increased PTEN levels both in vitro and in
vivo. One possible explanation is that when PTEN is expressed, the
resulting suppression in cell growth may induce the cells to become
more dependent on growth factor signaling, which can be
antagonized by SPARC.
Our in vitro data indicated that SPARC inhibited proliferation
and sensitized neuroblastoma cells to radiation via reducing the
phosphorylation levels of AKT, thereby leading to increased
PTEN. Moreover, our in vitro data also showed that both SPARC
and PTEN were expressed at the same time and followed
inhibition of pAKT in tumor cells when treated with pSPARC.
We expected the same results in vivo. To test this hypothesis, we
orthotopically grafted mice with NB1691 neuroblastoma cells and
treated them with mock, pEV or pSPARC alone or in
combination with radiation. The animals treated with pSPARC
showed increased SPARC levels as compared to mock or empty
vector-treated tumors. Immunohistochemical analysis for PTEN
and pAKT demonstrated that SPARC and PTEN were overex-
pressed when treated with pSPARC and at the same time, pAKT
was inhibited, leading to reduced proliferation in vivo. Other
studies support our findings since SPARC-overexpressing glioma
cells have been reported to inhibit cell proliferation upon PTEN
induction [37]. Accordingly, the addition of SPARC was shown to
modulate the proliferation of many primary cells including
endothelial cells [56,57], skeletal myoblasts [58], mesangial cells
[59], mesenchymal cells [60], mesothelial cells [44], and epithelial
cells [61]. The effect that changes in SPARC levels have on tumor
cell proliferation is more complex and debatable.
Earlier studies [62] showed that SPARC expression is inversely
correlated with the degree of malignant progression in neuroblas-
toma tumors. Knockdown of SPARC in neuroblastoma cells may
increase the malignant progression in neuroblastoma tumors.
SPARC has also been shown to have a role in growth rate
modulation as demonstrated by SPARC knockout mice having an
increased rate of tumor growth than those mice with intact
SPARC [63,64]. Based on the literature available, it may be
possible that forced knockdown of SPARC in these conditions may
lead to more tumor growth. Said and Motamed [65] evaluated the
effect of host-derived SPARC on ovarian cancer growth in vivo,
demonstrating more rapid and aggressive tumor growth in
SPARC-deficient animals.
In summary, we have shown that overexpression of SPARC
decreases proliferation and sensitizes neuroblastoma cells to
irradiation. We hypothesized that overexpression of SPARC
resulted in inhibition of pAKT and increased PTEN, leading to
cell cycle abate that subsequently caused the inhibition of
proliferation and sensitized cells to radiation in vitro and in vivo.
On the basis of these observations, we conclude that endogenous
Figure 7. SPARC overexpression alone and in combination with
radiation inhibits neuroblastoma cell proliferation in vivo
through increased expression of PTEN and inhibited phos-
phorylation of AKT. Neuroblastoma orthotopic tumor sections from
mice injected with mock, pEV or pSPARC plasmids alone or in
combination with radiation (IR) were analyzed as described in Materials
and Methods. (A) Tumor photographs from representing mice, (B)
Hematoxylin and Eosin (H&E) staining for the tumors (Magnification at
46and 406), and (C) immunohistochemical analysis for SPARC, Ki-67,
pAKT and PTEN were carried out as described in Materials and Methods.
All results are representative of multiple tumors taken from five
separate mice in each treatment group (Magnification at 606).
doi:10.1371/journal.pone.0036093.g007
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36093overexpression of SPARC can decrease neuroblastoma cell
proliferation and tumor growth and therefore act as a tumor
suppressor in human neuroblastoma. Future studies in human
neuroblastoma should focus on the design of treatment strategies
that specifically target SPARC–PTEN interactions.
Materials and Methods
Ethics statement
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria, Peoria, IL,
USA, approved all surgical interventions and post-operative care.
The consent was written and approved. The animal protocol
number is 872, dated May 20




SK-N-AS and IMR-32 cells were obtained from ATCC
(Manassas, VA) and NB-1691 cells were obtained from Dr.
Houghton of St. Jude Children’s Research Hospital (Memphis,
TN). Cells were cultured in RPMI medium with 10% fetal bovine
serum, 2 mM/L L-glutamine, 100 units/mL penicillin, and
100 mg/mL streptomycin. Cells were maintained in a humidified
atmosphere containing 5% CO2 at 37uC.
Antibodies and reagents
Antibodies against SPARC, pAKT, AKT, c-Myc, PTEN,
EGFR, pEGFR, Cyclin B, Cyclin D1, Cdc2, pCdc2, Cdc25C,
Chk1, Chk2, mTOR, PI3K, JNK, pJNK, c-Jun, p-c-Jun (Ser-63),
p-c-Jun (Ser-73), caspase-3, and GAPDH were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA), Antibodies against
PARP (Cell Signaling Technology, Beverly, MA) were also used in
this study. Plasmids encoding myr-AKT delta4–129 (Addgene
plasmid 10841) and HA PTEN wt (Addgene plasmid 10750) were
obtained from Addgene Inc. (Cambridge, MA).
Construction of pcDNA3.1-SPARC and transfection
An 1100-bp cDNA fragment of human SPARC was amplified
by PCR using synthetic primers and sub-cloned into a pcDNA3.1
vector (Invitrogen, San Diego, CA) in the ‘‘sense’’ orientation.
Neuroblastoma cells were transfected with full-length cDNA
SPARC-containing vector using FuGene HD (Roche, Indianap-
olis, IN) as per the manufacturer’s protocol.
siRNA design and transient transfection
SPARC siRNA sequences were designed with the help of a
siRNA designer program (Imgenex, Sorrento Valley, CA). The
siRNA was complementary to an exonic sequence of the target
mRNA and compatible with the pcDNA3.1 vector (Invitrogen,
San Diego, CA). The following siRNA sequence was used to
construct SPARC siRNA and designated as SP-siRNA: 59-
TCGAGGGTGTGCAGCAATGACAA CAAGAGTCGTCGT
TGTTGTCATTGCTGCACACCG-39. A control vector con-
taining siRNA with a scrambled sequence was constructed and




All transfection experiments were performed using FuGene HD
transfection reagent according to the manufacturer’s protocol
(Roche). Briefly, plasmid/siRNA was mixed with FuGene HD
reagent (1:3 ratio) in 500 mL of serum-free medium and left for
30 min to allow for complex formation. The complex was then
added to the 100-mm plate, which had 2.5 mL of serum-free
medium (2 mg plasmid per ml of medium). After 6 hours of
transfection, complete medium was added and cells were cultured
for another 36 hours.
Immunocytochemistry
We used a previously described protocol with minor changes
[66]. Briefly, the cells were cultured on 8-well chamber slides and
fixed with 4% paraformaldehyde (w/v) in PBS, permeabilized with
0.1% Triton X-100 (w/v) in PBS and blocked with 1% BSA (w/v)
in PBS for 1 hour at 4uC. Cells were incubated overnight at 4uC
with anti-SPARC antibody followed by corresponding Alexa fluor-
594-conjugated secondary antibody for 1 hour and counterstained
with DAPI. For negative controls primary antibody was replaced
by non-specific IgG. Slides were washed and mounted with anti-
fade mounting solution (Invitrogen, San Diego, CA) and analyzed
with an inverted microscope.
Western blotting
Western blot analysis was performed as described previously
[67]. Briefly, 36 hours after transfection, cells were collected and
lysed in RIPA buffer. Equal amounts of protein were resolved on
SDS-PAGE and transferred onto a PVDF membrane. The blot
was blocked with 5% non-fat dry milk and probed overnight with
primary antibodies followed by HRP-conjugated secondary
antibodies. An ECL system was used to detect chemiluminescent
signals. All blots were re-probed with GAPDH antibody to
confirm equal loading.
RT-PCR
Neuroblastoma cells were transfected with mock, pEV or
pSPARC for 36 hours. Total RNA was extracted from these cells
and cDNA synthesized using poly-dT primers as described earlier
[68]. PCR was performed using the following primers: SPARC:
59-GGAAGAAACTGTGGCAGAGG-39 (sense), and 59-
ATTGCTGCACACCTTCTCAA-39 (antisense); GAPDH: 59-
TGAAGGTCGGAGTCAACGGATTTGGT-39 (sense), and 59-
CATGTGGGCCATGAGGTCCACCAC-39 (antisense). Quanti-
fication of SPARC mRNA levels was determined based on
densitometry.
Flow cytometry
For assessment of DNA content, neuroblastoma cells were
plated overnight in 100-mm tissue culture plates and transfected
for 36 hours as described above. We used FACS analysis that
utilizes propidium iodide staining of nuclear DNA to characterize
hypo-diploid cells [69]. Briefly, cells were harvested by trypsin-
ization and stained with propidium iodide (2 mg/mL) in 4 mM
sodium citrate containing 3% (w/v) Triton X-100 and RNase A
(0.1 mg/mL; Sigma, St. Louis, MO). Suspensions of 2610
6 cells
were analyzed by FACS Caliber System (Becton Dickinson
Bioscience, San Jose, CA) with laser excitation at 488 nm and
using an emission 639 nm band pass filter to collect the red
propidium iodide fluorescence. The percentages of cells in the
various phases of the cell cycle (sub-G1, G1/S, and G2/M) were
assessed using Cell Quest software (Becton Dickinson Bioscience).
Cell proliferation assays
Cell growth rate was determined using a modified 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say as a measurement of mitochondrial metabolic activity as
described earlier [70]. Cells were transfected with indicated
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reagent was added to the cells and incubated for 6 hours at 37uC.
The rate of absorbance of formazan (a dye produced by live cells)
was measured with a microplate reader at A550.
Clonogenic assay
Cells were transfected with mock, pEV, and pSPARC for
24 hours and irradiated with different Gy of radiation. Cells
(5610
2 cells) were trypsinized and seeded in 100 mm Petri dishes.
On day 10 after irradiation, cells were fixed in cold methanol and
stained with Giemsa and colonies (.50 cells) were counted. The
plating efficiency (PE) is defined as the number of colonies
observed/the number of cells plated. Surviving fraction (SF) is the
colonies counted divided by the number of colonies plated with a
correction for the plating efficiency.
Survival fraction (SF)~Colonies counted=
½Cells seeded|(PE=100) 
Intra-adrenal tumor model and immunohistochemistry
The Institutional Animal Care and Use Committee at the
University of Illinois College of Medicine at Peoria approved all
experimental procedures involving the use of animals. Orthotopic,
localized neuroblastoma tumors were established in C.B-17 SCID
mice by injection of 1610
6 NB-1691 cells in 100 mL PBS into the
retroperitoneal space as described earlier [71]. After 2 weeks of
tumor cell implantation, the mice were separated into six groups
containing 6 animals per group, and each group was injected
intravenously with PBS (mock) or pEV or pSPARC (100 mL
volume) and was given three doses on alternate days. Between the
first and the second injections, and the second and the third
injections, one group was radiated with a dose of 5 Gy each time.
Mice were euthanized when animals had lost .20% of body
weight or had trouble ambulating, feeding, or grooming. The
tumors were removed and either fixed in 10% phosphate-buffered
formaldehyde or snap frozen and maintained at 270uC until
sectioning. Briefly, all tumors were serially sectioned and tissue
sections (7 mm thick) obtained from the paraffin blocks were
stained with hematoxylin and eosin (H&E) using standard
histologic techniques. For immunohistochemical analysis, sections
were incubated with mAb (1 hour at room temperature) followed
by the appropriate secondary antibody. For HRP-conjugated
secondary antibodies, we used DAB solution as the chromogen.
Negative control slides were obtained by nonspecific IgG. Sections
were mounted with mounting solution and analyzed with an
inverted microscope.
Statistical analysis
All data are expressed as mean 6 SD. Statistical analysis was
performed using the student’s t test or a one-way analysis of
variance (ANOVA). A p value of less than 0.05 was considered
statistically significant. All experiments were performed in
triplicate to obtain consistent results.
Supporting Information
Figure S1 Overexpression of SPARC in neuroblastoma
cells. The human full-length SPARC cDNA was subcloned into
the pDNR-CMV mammalian expression vector and termed as
pSPARC. pDNR-CMV was the vector without the SPARC gene
and termed as empty vector (pEV). SK-N-AS, NB1691 and IMR-
32 cells were transfected with mock (PBS control), empty vector
(pEV) or SPARC full-length gene inserted vector (pSPARC) for
36 hours. (A) SPARC levels were determined by Western blotting
using a SPARC-specific antibody. GAPDH served as a loading
control. Columns, mean of three experiments; bars, SD.* p,0.01
vs pEV. (B) cDNA was produced from total RNA extracted from
the mock and infected cells. RT-PCR analysis was performed for
SPARC. Results are representative of three independent exper-
iments. GAPDH served as a control for RNA quality. Columns,
mean of three experiments; bars, SD. * p,0.01 vs pEV. (C) SK-N-
AS, NB1691 and IMR-32 cells were transfected with mock (PBS
control), empty vector (pEV) or pSPARC for 36 hours and
immunocytochemical analysis for SPARC was performed. Rep-
resenting images were shown taken from 5 different microscopic
fields of three independent experiments. (D) SK-N-AS, NB1691
neuroblastoma cells and HMEC cells were culture for 24 hours
and Western blot analysis was performed for SPARC using
specific antibody. GAPDH served as loading control. (E)
Clonogenic survival assay for irradiated neuroblastoma cells.
SK-N-AS, NB1691 and IMR-32 neuroblastoma cells were
irradiated (IR) with 2 Gy to 12 Gy doses of radiation and
clonogenic assay was performed as described in Materials and
Methods. The cells were culture and colonies larger than 50 cells
were counted. Points: mean of triplicate experiments.
(TIF)
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